American Journal of Clinical Dermatology

, Volume 15, Supplement 1, pp 3–4


  • Alice Bendix Gottlieb


  1. 1.
    Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31 e1–15.Google Scholar
  4. 4.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. NEJM. 2003;349(21):2014–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–32 (discussion 32).PubMedCrossRefGoogle Scholar
  6. 6.
    Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696.
  8. 8.
    Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthr Rheum. 2012;64(8):2504–17.CrossRefGoogle Scholar
  9. 9.
    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2005;52(10):3279–89.CrossRefGoogle Scholar
  11. 11.
    Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–43.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Wu JJ. Tumor necrosis factor inhibitors and myocardial infarction in psoriasis. JAMA. 2013;310(10):1075–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum. 2007;56(9):2905–12.CrossRefGoogle Scholar
  14. 14.
    Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82.PubMedCrossRefGoogle Scholar
  15. 15.
    de Eusebio E, Armario-Hita JC, de Miquel DVA. Treatment of Psoriasis: focus on clinic-based management with Infliximab. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0054-4.
  16. 16.
    Campos Muñoz L, de Unamuno Bustos B, Herranz Pinto P, et al. Infliximab treatment of Psoriasis in supervised infusion centers: case management experience. Am J Clin Dermatol. 2014. doi:10.1007/s40257-013-0055-3.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Alice Bendix Gottlieb

There are no affiliations available

Personalised recommendations